Fourth quarter and full year 2023 results
Fourth quarter and full year 2023 results were reviewed by management during a live audio webcast with the financial community on February 1st, 2024. The presentation was followed by a Q&A session.
14:30 - 16:00 CET (8:30am – 10am EST)
Featuring
Paul Hudson
Chief Executive Officer
Jean-Baptiste de Chatillon
Chief Financial Officer
Brian Foard
Specialty Care
Olivier Charmeil
General Medicines
Houman Ashrafian
Head of Research and Development
Thomas Triomphe
Vaccines
Julie van Ongevalle
Consumer Healthcare
Roy Papatheodorou
General Counsel
Highlights
Paul Hudson comments on 2023 results
Full-Year 2023 results and R&D highlights
2023 was a turning-point year for Sanofi, paving the way for our scientific leadership in Immunology. Coupled with our AI at-scale ambitions, we go forward as a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth.
Paul Hudson
Chief Executive Officer